Global research landscape of antiangiogenic therapy for colorectal cancer: a bibliometric analysis of mechanistic insights and clinical advancements
文献类型：期刊论文
| 作者 | Hou, Ke-Qiang3; Wu, Jia-Ming2; Chen, Jie1 |
| 刊名 | FRONTIERS IN ONCOLOGY
 |
| 出版日期 | 2025-07-24 |
| 卷号 | 15页码:13 |
| 关键词 | colorectal cancer antiangiogenesis therapy basic mechanism clinical treatment bibliometric analysis VOSviewer CiteSpace |
| ISSN号 | 2234-943X |
| DOI | 10.3389/fonc.2025.1591059 |
| 通讯作者 | Wu, Jia-Ming(wujm1980@163.com) ; Chen, Jie(chenj383@zjxu.edu.cn) |
| 英文摘要 | Background Colorectal cancer (CRC) is a major global health issue, with over 1.9 million diagnoses yearly and low survival rates in advanced stages. Antiangiogenic therapies (AAT) targeting VEGF and VEGFR have improved outcomes, but resistance mechanisms limit their effectiveness. This study uses bibliometric analysis to link mechanistic insights, such as VEGF splicing variants, with clinical developments, identify global collaboration trends, and propose strategies to reduce resistance and toxicity in treatments.Methods This study were used to search the Web of Science databases Core Collection. Studies published in English from 1996 to 2024 were included for analysis. VOSviewer 1.6.20, CiteSpace 6.4.R1, and R 4.4.1 were employed for bibliometric analysis and visualization.Results This bibliometric analysis of 976 publications from 1996 to 2024 shows a 13.65% annual growth rate in CRC antiangiogenic research. China leads with 20.5% of publications, followed by the USA at 15.7% and Japan at 13.1%. Key institutions include Assistance Publique H & ocirc;pitaux de Paris, and notable journals are BMC Cancer and Clinical Colorectal Cancer. Keyword evolution reflects a shift from angiogenesis mechanisms to clinical validation of treatments like FOLFIRI with bevacizumab, with a current focus on tumor microenvironment reprogramming and precision survival analytics (2020-2024, burst intensity 6.66). Key milestones include Phase III trials like AVF2107g and ctDNA-guided strategies, along with emerging dual-target inhibitors.Conclusion This bibliometric analysis reveals a shift from VEGF studies to precision strategies targeting tumor microenvironments, influenced by trials like TRIBE and PARADIGM. Future efforts should focus on multi-omics integration and innovative delivery systems like circadian-targeted nanoparticles for personalized CRC care. |
| WOS关键词 | SUBGROUP ANALYSES ; PLUS BEVACIZUMAB ; PHASE-II ; FLUOROURACIL ; LEUCOVORIN ; ANGIOGENESIS ; CHEMOTHERAPY ; IRINOTECAN ; FOLFOXIRI ; PLACEBO |
| 资助项目 | National Oncology Clinical Key Specialty[2023-GJZK-001] ; Zhejiang Provincial Medical and Health Science and Technology Program[2025KY1600] |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| WOS记录号 | WOS:001545121500001 |
| 出版者 | FRONTIERS MEDIA SA |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/321204]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Wu, Jia-Ming; Chen, Jie |
| 作者单位 | 1.Jiaxing Univ, Affiliated Hosp 1, Dept Cent Lab, Jiaxing, Zhejiang, Peoples R China 2.Jiaxing Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, Jiaxing, Zhejiang, Peoples R China 3.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai, Peoples R China |
| 推荐引用方式 GB/T 7714 | Hou, Ke-Qiang,Wu, Jia-Ming,Chen, Jie. Global research landscape of antiangiogenic therapy for colorectal cancer: a bibliometric analysis of mechanistic insights and clinical advancements[J]. FRONTIERS IN ONCOLOGY,2025,15:13. |
| APA | Hou, Ke-Qiang,Wu, Jia-Ming,&Chen, Jie.(2025).Global research landscape of antiangiogenic therapy for colorectal cancer: a bibliometric analysis of mechanistic insights and clinical advancements.FRONTIERS IN ONCOLOGY,15,13. |
| MLA | Hou, Ke-Qiang,et al."Global research landscape of antiangiogenic therapy for colorectal cancer: a bibliometric analysis of mechanistic insights and clinical advancements".FRONTIERS IN ONCOLOGY 15(2025):13. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。